Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of preparation method of adenosine receptor antagonist

A solid and compound technology, applied in the field of new heterocyclic compounds, can solve the problems of less antagonists and lower survival rate after treatment

Active Publication Date: 2021-07-30
XIAMEN BIOTIME BIOTECHNOLOGY CO LTD
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that A2B antagonists can prevent the growth of tumors (bladder cancer, breast cancer), and the high expression of A2B in triple-negative breast cancer patients can also lead to reduced survival rates after treatment
[0008] International patent application publication numbers WO2011 / 095625, WO2001 / 92264, WO2003 / 048165, WO2004 / 09443, WO2002 / 055083, etc. disclose compounds for A2A receptor antagonists, and international patent application publication numbers WO2005 / 040155, WO2016 / 164838, WO2016 / 150901, WO20161 / 35048, WO2015 / 05206, WO2012 / 076974, WO2011 / 005871, Chinese Patent Application Publication No. CN102532137 and U.S. Patent Application Publication No. US20140142113, etc. disclose compounds that are used as A2B receptor antagonists, but simultaneously inhibit A2A and A2B Receptor antagonists have been rarely reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of preparation method of adenosine receptor antagonist
  • A kind of preparation method of adenosine receptor antagonist
  • A kind of preparation method of adenosine receptor antagonist

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment

[0139] When preparation routes are not included, relevant intermediates are commercially available (e.g. from Sigma Aldrich, Alfa)

[0140] general process

[0141] Commercially available reagents were used without further purification. Room temperature means 20-27°C. 1H-NMR spectra were recorded on a Bruker instrument at 500 MHz. Chemical shift values ​​are expressed in parts per million, ie δ values. The following abbreviations are used for the multiplicity of NMR signals: s = singlet, brs = broad, d = doublet, t = triplet, m = multiplet. Coupling constants are listed as J values, measured in Hz. NMR and mass spectral results were corrected for background peaks. Chromatography refers to column chromatography using 100 mesh silica gel and done under nitrogen pressure (flash chromatography). TLC used to monitor the reaction refers to TLC performed using the specific mobile phase and silica gel F254 from Merck as stationary phase.

[0142] LC-MS experiments were measured...

Embodiment 1

[0173] Embodiment 1: the preparation of compound 1

[0174]

[0175] Compound 1a (8.0g, 57.9mmol) was dissolved in a mixed solution of dioxane (180mL) and water (5mL), then selenium dioxide (7.07g, 63.7mmol) was added; the reaction temperature was raised to 55 degrees and stirred until Selenium dioxide is completely dissolved. Then the reaction system was stirred overnight at the reflux temperature, and the reaction of the raw materials was detected by thin layer chromatography. The reaction solution was filtered, and the filtrate was concentrated to obtain an oily crude product, which was added to water (120 mL) and extracted with ethyl acetate (100 mL x 3). The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain light yellow oily compound 1b (6.5 g, yield: 66%).

[0176] Compound 1b (6.5 g, 38 mmol) was dissolved in ethanol (100 mL), and sodium bicarbonate (8.0 g, 96 mmol...

Embodiment 2

[0195] Embodiment 2: the preparation of compound 45

[0196]

[0197] Chlorosulfonic acid isocyanate (15.5 mg, 0.11 mmol) was added to a solution of compound 1h in dichloromethane (3 mL) at 0°C. The reaction solution was stirred at 0°C for 2 hours, and the reaction of the raw materials was detected by LC-MS. The reaction solution was diluted with dichloromethane (30 mL), and washed with saturated brine (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate, and the filtrate was concentrated to obtain a crude product, which was separated by preparative high performance liquid chromatography (5-95% acetonitrile, 0.1% formic acid) to obtain light yellow solid compound 45 (8 mg, yield: 22%). 1 HNMR (500MHz, MeOH-d 4 ):δ7.65-7.58(m,2H),7.34(s,1H),7.31(s,1H),7.21-7.15(m,2H),2.46(s,3H); MS 359.3[M+H] +

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a heterocyclic compound as an A2A and / or A2B receptor antagonist, specifically, the present invention provides a compound shown in the following formula I, wherein the definition of each group is as described in the description . The compound of the present invention has A2A and / or A2B inhibitory activity, and can be used to prevent or treat diseases related to A2A and / or A2B activity or expression.

Description

[0001] This application is a divisional application, the Chinese application number of the parent case is 201980004345.5, the international application number is PCT / CN2019 / 074927, and the international application date is February 13, 2019. [0002] The present invention claims the priority of the Chinese patent application CN201810165937.2, and the content described in the specification and claims of the priority document is incorporated into the specification of the present invention in its entirety and is regarded as a part of the original record of the specification of the present invention. The applicant further declares that the applicant has the right to amend the description and claims of the present invention based on the priority document. technical field [0003] The present invention provides a novel heterocyclic compound, its synthesis and its application as an adenosine receptor (A2A and / or A2B) antagonist. Background technique [0004] Checkpoint inhibitors h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/04C07D405/14C07D253/07C07D405/04C07D401/14C07D409/14
CPCC07D253/07C07D401/04C07D401/14C07D405/04C07D405/14C07D409/14
Inventor 刘世峰俞智勇
Owner XIAMEN BIOTIME BIOTECHNOLOGY CO LTD